Welcome to our dedicated page for Repligen SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Repligen Corporation (NASDAQ: RGEN), a global life sciences company focused on bioprocessing technologies and systems for manufacturing biological drugs. As a Nasdaq-listed issuer, Repligen submits a range of regulatory documents that give detailed insight into its financial performance, governance and material events.
Among the key filings available are Form 10-K annual reports and Form 10-Q quarterly reports, which typically include audited or reviewed financial statements, management’s discussion and analysis, and information on Repligen’s bioprocessing focus areas: Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. These filings expand on the themes highlighted in the company’s earnings press releases and non-GAAP reconciliations.
Repligen also files Form 8-K current reports to disclose material events. Recent examples include 8-K filings referencing the release of second and third quarter 2025 financial results, as well as an 8-K describing the appointment of a Chief Accounting Officer to enhance the company’s financial reporting infrastructure and Sarbanes–Oxley oversight. Such filings can provide timely context on leadership changes, compensation decisions and other corporate developments.
Investors may also review proxy statements and, where applicable, Form 4 insider transaction reports to understand equity-based compensation and share activity by directors and officers. Together, these documents form the regulatory record of Repligen’s operations as a public company.
On Stock Titan, Repligen’s filings are updated as they are released on EDGAR, with AI-powered summaries that highlight key points from lengthy reports. This helps readers quickly identify major financial trends, governance changes and disclosures related to Repligen’s role as a life sciences and bioprocessing technology company.
Repligen Corp Chief Executive Officer Olivier Loeillot reported two Form 4 transactions where shares were withheld to cover taxes on restricted stock units. On February 27, 2026, 344 shares of common stock were disposed of at $128.73 per share, leaving 35,554 shares directly owned. On March 2, 2026, 1,610 shares were disposed of at $124.97 per share, leaving 33,944 shares directly owned. These are tax-withholding dispositions, not open-market sales.
REPLIGEN CORP director Anthony Hunt reported a tax-related share disposition. On the release of restricted stock units, 9,897 shares of common stock were withheld by the company to cover his tax withholding obligations at a reference price of $124.97 per share. After this non‑open‑market transaction, he directly owned 89,062 shares.
Repligen Corporation’s CFO Jason K. Garland reported routine tax-related share withholdings. On March 2, 2026, the company withheld 715 shares of common stock at $124.97 per share, and on February 27, 2026, it withheld 327 shares at $128.73 per share to satisfy tax obligations triggered by restricted stock unit releases. These dispositions were for tax withholding rather than open-market sales.
Repligen Corp senior vice president of R&D Ralf Kuriyel reported two tax-related share dispositions. On February 27, 2026, the company withheld 444 shares of common stock at $128.73 to cover tax obligations from restricted stock units vesting.
On March 2, 2026, the company similarly withheld 923 shares at $124.97. After the later transaction, Kuriyel directly owned 14,695 common shares. These were tax-withholding events rather than open-market sales.
Repligen Corp chief product officer Brian Robb reported a small share disposition tied to taxes rather than an open-market trade. On the reported date, 221 shares of common stock were withheld by the company at $124.97 per share to cover tax obligations arising from the release of restricted stock units. After this tax-withholding transaction, Robb’s directly held common stock balance was 8,319 shares.
Repligen Corporation provides an annual overview of its global bioprocessing business, describing franchises in filtration, chromatography, process analytics and proteins that serve biologics and emerging gene and cell therapy markets. The company estimates a roughly $13 billion addressable market within a $20 billion global bioprocessing space.
Repligen highlights growth via innovation, integrated solutions and targeted acquisitions, including the 2025 purchase of 908 Devices’ bioprocess PAT portfolio, while operating 19 manufacturing sites and employing about 2,000 people worldwide. The filing also outlines key risks, such as customer and supplier concentration, competition, foreign exchange exposure, $600 million of 1.00% convertible notes due 2028 and material weaknesses in internal controls.
Repligen Corporation reported strong fourth-quarter and full-year 2025 results and issued upbeat 2026 guidance. Q4 2025 revenue reached $198 million, up 18% year over year (14% organic). Full-year 2025 revenue was $738 million, a 16% increase with 14% organic growth.
Profitability improved sharply. Full-year GAAP income from operations was $55 million versus a loss of $35 million in 2024, while GAAP net income was $48.9 million compared to a $25.5 million loss. Adjusted net income rose to $96.9 million, with adjusted diluted EPS of $1.71 versus $1.58.
Margins expanded, with 2025 GAAP gross margin at 52.3% and adjusted operating margin at 13.8%. For 2026, Repligen guides revenue of $810–$840 million (10–14% reported growth, 9–13% organic), adjusted operating margin of 15.1–15.5%, adjusted EBITDA margin of 20–20.5%, and diluted EPS of $1.93–$2.01. Cash, cash equivalents and marketable securities totaled $768 million at December 31, 2025.
T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting a significant ownership position in Repligen Corp. common stock. The firm reports beneficial ownership of 4,599,860 shares, representing 8.2% of the outstanding common stock as of December 31, 2025.
T. Rowe Price states it has sole voting power over 4,301,925 shares and sole dispositive power over 4,599,061 shares, with no shared voting or dispositive power. It certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Repligen.
Repligen Corporation’s common stock ownership has been updated by several Eddleman-related trusts in an amended Schedule 13G.
The Roy T. Eddleman Living Trust reports beneficial ownership of 2,705,689 shares of Repligen common stock, representing 4.81% of the class. The Roy T. Eddleman Charitable Remainder Trust #1 reports beneficial ownership of 29,604 shares, representing 0.001% of the class, while Charitable Remainder Trust #2 reports no shares. Co‑trustees Geoffrey Paul, Nereyda Rubio and Anis Garci share voting and investment power over a total of 2,735,293 shares. The filing states these securities are held on a passive basis and not for the purpose of changing or influencing control of Repligen.
FMR LLC and Abigail P. Johnson report a 5.1% beneficial stake in Repligen Corp common stock. As of December 31, 2025, they report beneficial ownership of 2,891,140.17 shares, representing 5.1% of the outstanding common stock. FMR LLC has sole voting power over 2,876,401.55 shares and sole dispositive power over 2,891,140.17 shares, while Abigail P. Johnson has sole dispositive power over the same 2,891,140.17 shares with no voting power. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Repligen. One or more other persons may have rights to dividends or sale proceeds, but no single such interest exceeds five percent of the class.